P-glycoprotein limits the absorption of the anti-HIV drug zidovudine through rat intestinal segments

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 3, 2011, Pages 151-159

  Quevedo, Mario A ^a   Nieto, Leandro E ^a   Briñón, Margarita C ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Azidothymidine (AZT); Gut sac technique; Intestinal permeation; P glycoprotein (P gp)

Indexed keywords

GLYCOPROTEIN P; VERAPAMIL; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; ILEUM; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SOLVATION;

ANIMALS; ANTI-HIV AGENTS; BINDING SITES; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; HUMANS; ILEUM; INTESTINAL ABSORPTION; JEJUNUM; MALE; MODELS, MOLECULAR; MUCOUS MEMBRANE; P-GLYCOPROTEIN; PERMEABILITY; PRODRUGS; RATS; RATS, WISTAR; SEROUS MEMBRANE; VERAPAMIL; ZIDOVUDINE;

EID: 79956347493     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.04.007     Document Type: Article

References (47)

1. Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang, Q., Urbatsch, I.L., Chang, G., 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722.
2. Antonelli, G., Turriziani, O., Cianfriglia, M., Riva, E., Dong, G., Fattorossi, A., Dianzani, F., 1992. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res. Hum. Retroviruses 8, 1839-1844.
3. Balimane, P.V., Sinko, P.J., 1999. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv. Drug Deliv. Rev. 39, 183-209.
4. Barthe, L., Bessouet, M., Woodley, J.F., Houin, G., 1998. The improved everted gut sac: a simple method to study intestinal P-glycoprotein. Int. J. Pharm. 173, 255-258.
5. Blum, M.R., Liao, S.H., Good, S.S., de Miranda, P., 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85, 189-194.
6. Bonate, P.L., 2006. The art of modeling. In: Pharmacokinetic- pharmacodynamic modeling and simulation, first ed.. Springer, New York.
7. Booth-Genthe, C.L., Louie, S.W., Carlini, E.J., Li, B., Leake, B.F., Eisenhandler, R., Hochman, J.H., Mei, Q., Kim, R.B., Rushmore, T.H., Yamazaki, M., 2006. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. J. Pharmacol. Toxicol. Methods 54, 78-89.
8. Boudinot, F.D., Schinazi, R.F., Gallo, J.M., McClure, H.M., Anderson, D.C., Doshi, K.J., Kambhampathi, P.C., Chu, C.K., 1990. 3′-Azido-2′, 3′-dideoxyuridine (AzddU): comparative pharmacokinetics with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res. Hum. Retroviruses 6, 219-228.
9. Breedveld, P., Beijnen, J.H., Schellens, J.H., 2006. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27, 17-24.
10. Case, D.A., Cheatham, T.E., Darden, T., Gohlke, H., Luo, R., Merz, K.M., Onufriev Jr., A., Simmerling, C., Wang, B., Woods, R.J., 2005. The Amber biomolecular simulation programs. Comput. Chem. 26, 1668-1688.
11. Chan, L.M.S., Lowes, S., Hirst, B.H., 2004. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21, 25-51.
12. Dahan, A., Amidon, G.L., 2009. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G371-G377.
13. De Clercq, E., 2002. Molecular targets and compounds for anti HIV therapy. In: Matsoukas, J., Mavromoustakos, T. (Eds.), Drug Discovery and Design: Medical Aspects, first ed.. IOS Press, Amsterdam, The Netherlands.
14. De Clercq, E., 2007. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6, 1001-1018.
15. De Clercq, E., 2009. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 33, 307-320.
16. De Souza, J., Benet, L.Z., Huang, Y., Storpirtis, S., 2009. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J. Pharm. Sci. 98, 4413-4419.
17. Demel, M.A., Schwaha, R., Krämer, O., Ettmayer, P., Haaksma, E.E., Ecker, G.F., 2008. In silico prediction of substrate properties for ABC-multidrug transporters. Expert Opin. Drug Metab. Toxicol. 4, 1167-1180.
18. Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., Stewart, J.J.P., 1985. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107, 3902-3909.
19. Eilers, M., Roy, U., Mondal, D., 2008. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. Exp. Biol. Med. (Maywood) 233, 1149-1160.
20. Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J.R., Zakrzewski, V.G., Montgomery Jr., J.A., Stratmann, R.E., Burant, J.C., Dapprich, S., Millam, J.M., Daniels, A.D., Kudin, K.N., Strain, M.C., Farkas, O., Tomasi, J., Barone, V., Cossi, M., Cammi, R., Mennucci, B., Pomelli, C., Adamo, C., Clifford, S., Ochterski, J., Petersson, G.A., Ayala, P.Y., Cui, Q., Morokuma, K., Malick, D.K., Rabuck, A.D., Raghavachari, K., Foresman, J.B., Cioslowski, J., Ortiz, J.V., Baboul, A.G., Stefanov, B.B., Liu, G., Liashenko, A.P., Piskorz, I., Komaromi, R., Gomperts, R.L., Fox Martin, D.J., Keith, T., Al-Laham, M.A., Peng, C.Y., Nanayakkara, A., Gonzalez, C., Challacombe, M., Gill, P.M.W., Johnson, B., Chen, W., Wong, M.W., Andres, J.L., Gonzalez, C., Head-Gordon, M., Replogle, E.S., Pople, J.A., 1998. Software: GAUSSIAN 98. Gaussian, Inc., Pittsburgh, PA, USA. Available from: 〈www.gaussian.com/〉.
21. Haslam, I.S., Jones, K., Coleman, T., Simmons, N.L., 2008. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem. Pharmacol. 76, 850-861.
22. Huang, Q.Q., Yao, S.Y., Ritzel, M.W., Paterson, A.R., Cass, C.E., Young, J.D., 1994. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside. J. Biol. Chem. 269, 17757-17760.
23. Humphrey, W., Dalke, A., Schulten, K., 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38.
24. Jorajuria, S., Dereuddre-Bosquet, N., Becher, F., Martin, S., Porcheray, F., Garrigues, A., Mabondzo, A., Benech, H., Grassi, J., Orlowski, S., Dormont, D., Clayette, P., 2004. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir. Ther. 9, 519-528.
25. Kipp, H., Arias, I.M., 2002. Trafficking of canalicular ABC transporters in hepatocytes. Annu. Rev. Physiol. 64, 595-608.
26. Lifschitz, A., Virkel, G., Ballent, M., Sallovitz, J., Lanusse, C., 2009. Combined use of ivermectin and triclabendazole in sheep: in vitro and in vivo characterisation of their pharmacological interaction. Vet. J. 182, 261-268.
27. Maag, F., Li, H., Alfredson, T., 2008. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 97, 1109-1134.
28. MacLean, C., Moenning, U., Reichel, A., Fricker, G., 2008. Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Dispos. 36, 1249-1254.
29. Morse, G.D., Shelton, M.J., O'Donnell, A.M., 1993. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. 24, 101-123.
30. Pan, G., Giri, N., Elmquist, W.F., 2007. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos. 35, 1165-1173.
31. Panhard, X., Legrand, M., Taburet, A.M., Diquet, B., Goujard, C., Mentré, F., 2007. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur. J. Clin. Pharmacol. 63, 1019-1029.
32. Pastor-Anglada, M., Cano-Soldado, P., Molina-Arcas, M., Lostao, M.P., Larráyoz, I., Martínez-Picado, J., Casado, F.J., 2005. Cell entry and export of nucleoside analogues. Virus Res. 107, 151-164. (Pubitemid 40093088)
33. Quevedo, M.A., Briñón, M.C., 2009. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res. 83, 103-111.
34. Quevedo, M.A., Moroni, G.N., Briñón, M.C., 2001. Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem. Biophys. Res. Commun. 288, 954-960.
35. Quevedo, M.A., Teijeiro, S.A., Briñón, M.C., 2006. Quantitative plasma determination of a novel antiretroviral derivative of zidovudine by solid-phase extraction and high-performance liquid chromatography. Anal. Bioanal. Chem. 385, 377-384.
36. Quevedo, M.A., Ribone, S.R., Moroni, G.N., Briñón, M.C., 2008. Binding to human serum albumin of AZT and novel AZT derivatives. Experimental and theoretical analyses. Bioorg. Med. Chem. 16, 2779-2790.
37. Santos, C., Morais, J., Gouveia, L., De Clercq, E., Pannecouque, C., Nielsen, C.U., Steffansen, B., Moreira, R., Gomes, P., 2008. Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity. ChemMedChem 3, 970-978.
38. Schuetz, J.D., Connelly, M.C., Sun, D., Paibir, S.G., Flynn, P.M., Srinivas, R.V., Kumar, A., Fridland, A., 1999. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048-1051.
39. Shafer, R.W., Schapiro, J.M., 2008. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10, 67-84.
40. Sharma, P., Chawla, H.P., Panchagnula, R., 2002. LC determination of cephalosporins in in vitro rat intestinal sac absorption model. J. Pharm. Biomed. Anal. 27, 39-50.
41. Stephens, R.H., O'Neill, C.A., Warhurst, A., Carlson, G.L., Rowland, M., Warhurst, G., 2001. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J. Pharmacol. Exp. Ther. 291, 584-591.
42. Szakács, G., Váradi, A., Ozvegy-Laczka, C., Sarkadi, B., 2008. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 13, 379-393.
43. Trott, O., Olson, A.J., 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 31, 455-461.
44. Varatharajan, L., Thomas, S.A., 2009. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82, A99-A109.
45. Wakabayashi, Y., Kipp, H., Arias, I.M., 2006. Transporters on demand: intracellular reservoirs and cycling of bile canalicular ABC transporters. J. Biol. Chem. 38, 27669-27673.
46. Wallace, A.C., Laskowski, R.A., Thornton, J.M., 1996. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127-134.
47. Zhou, S.F., 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38, 802-832.